RxDoctor Payments Data

Matthew Ballo, MD

Radiation Oncology · Memphis, TNNPI 1013017094

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 81.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $7,637 and has fallen 97.1% since, to $219 in 2025. Among radiation oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,707in general payments, 2019–2025

Across 76 payments — averaging $325.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$20K
  • Elekta, Inc.$2K
  • GT Medical Technologies, Inc$2K
  • Zap Surgical Systems, Inc.$437
  • Siemens Medical Solutions USA, Inc.$312
  • Medtronic$151
  • plus $199 from 6 others
$195,185in research payments, 2019–2025

Across 37 payments — averaging $5275.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure GmbH$175K
  • Novocure Inc.$20K

What the payments were for

  • Consulting fees$8,30034%
  • Speaking & faculty fees$10,50042%
  • Travel & lodging$2,50910%
  • Food & beverage$3,39814%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,707 in reported general payments places this provider in the 95th percentile of 115 radiation oncology providers in Tennessee.

See all radiation oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$775,146
Medicare patients
417
Services billed
4,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone21$659

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →